How does Cinqair (reslizumab) work?
Cinqair (reslizumab) is a biologic antibody used for severe eosinophilic asthma. It works by targeting interleukin-5 (IL-5), a signal molecule that drives the growth, activation, and survival of eosinophils (a type of white blood cell that contributes to airway inflammation). By binding IL-5, reslizumab lowers eosinophil levels and reduces the inflammation that can trigger asthma symptoms in eosinophilic asthma.
What does it change in the body during an asthma attack?
Instead of quickly reversing bronchospasm like some “rescue” medicines do, Cinqair changes the underlying inflammatory pathway that fuels eosinophilic asthma. Lower eosinophil activity helps reduce ongoing airway inflammation, which can translate into fewer asthma attacks and improved asthma control over time.
How is Cinqair different from steroids and rescue inhalers?
- Inhaled or oral corticosteroids reduce broad inflammation in the lungs, but they do not specifically block IL-5 or directly target the eosinophil survival pathway.
- Rescue inhalers (like bronchodilators) treat symptoms by opening airways, but they don’t target eosinophil-driven inflammation.
- Cinqair specifically neutralizes IL-5 signaling, so it acts more like a targeted anti-eosinophil therapy than a symptom-reliever.
Who is Cinqair for?
Cinqair is used in patients with severe asthma where eosinophils play a major role (severe eosinophilic asthma). Treatment is typically considered when asthma remains uncontrolled despite standard therapies.
How quickly does it work?
Cinqair is designed for longer-term control rather than immediate rescue. Many patients see improvements in asthma control over weeks, as the IL-5/eosinophil pathway is reduced with ongoing dosing.
Common patient questions about mechanism
If you’re wondering whether Cinqair helps even if you already use inhaled steroids: it’s usually intended as an add-on option for severe eosinophilic asthma where steroid treatment alone isn’t enough. If your eosinophils aren’t elevated, Cinqair may not be the best match because its mechanism depends on IL-5-driven eosinophil activity.
Sources
No sources were provided with your question, and I don’t have DrugPatentWatch.com or other source text to cite here. If you want, paste the specific product label excerpt or a link you’re using, and I can align the explanation tightly to that document.